Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (111-120 of 192) with videos related to

Pageof 20
Sort By:
Anticancer Research|June 9, 2016
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural EffusionMotohiro Tamiya, Akihiro Tamiya, Tomomi Yasue, et al.
Investigational New Drugs|January 6, 2021
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort studyTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Anticancer Research|March 10, 2015
The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancerNorio Okamoto, Hidekazu Suzuki, Kunimitsu Kawahara, et al.
Japanese Journal of Clinical Oncology|August 19, 2024
High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group)Kageaki Watanabe, Keita Sasaki, Ryunosuke Machida, et al.
Clinical Lung Cancer|November 15, 2017
Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With NivolumabTakako Inoue, Motohiro Tamiya, Akihiro Tamiya, et al.
Plos One|February 23, 2018
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trialMotohiro Tamiya, Akihiro Tamiya, Takako Inoue, et al.
Cancer Treatment and Research Communications|August 4, 2024
Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatmentSaki Tanaka, Motohiro Tamiya, Satoshi Nishiuma, et al.
Oxford Medical Case Reports|June 30, 2022
Successful weaning of a patient with severe COVID-19 pneumonia under prolonged midazolam sedation using morphineKei Kunimasa, Yoshifumi Ohashi, Megumi Okawa, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2015
A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) RearrangementTakayuki Shiroyama, Ayako Tanaka, Motohiro Tamiya, et al.
Medical Oncology (Northwood, London, England)|August 9, 2013
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusionMotohiro Tamiya, Akihiro Tamiya, Tadahiro Yamadori, et al.
Pageof 20

Showing results (111-120 of 192) with videos related to

Sort By:
Pageof 20
Anticancer Research|June 9, 2016
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural EffusionMotohiro Tamiya, Akihiro Tamiya, Tomomi Yasue, et al.
Investigational New Drugs|January 6, 2021
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort studyTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Anticancer Research|March 10, 2015
The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancerNorio Okamoto, Hidekazu Suzuki, Kunimitsu Kawahara, et al.
Japanese Journal of Clinical Oncology|August 19, 2024
High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group)Kageaki Watanabe, Keita Sasaki, Ryunosuke Machida, et al.
Clinical Lung Cancer|November 15, 2017
Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With NivolumabTakako Inoue, Motohiro Tamiya, Akihiro Tamiya, et al.
Plos One|February 23, 2018
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trialMotohiro Tamiya, Akihiro Tamiya, Takako Inoue, et al.
Cancer Treatment and Research Communications|August 4, 2024
Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatmentSaki Tanaka, Motohiro Tamiya, Satoshi Nishiuma, et al.
Oxford Medical Case Reports|June 30, 2022
Successful weaning of a patient with severe COVID-19 pneumonia under prolonged midazolam sedation using morphineKei Kunimasa, Yoshifumi Ohashi, Megumi Okawa, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2015
A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) RearrangementTakayuki Shiroyama, Ayako Tanaka, Motohiro Tamiya, et al.
Medical Oncology (Northwood, London, England)|August 9, 2013
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusionMotohiro Tamiya, Akihiro Tamiya, Tadahiro Yamadori, et al.
Pageof 20